Contemporaneously, Cephalon agreed to pay $425 million for off-label marketing of
modafinil. That means that for 18 months, the
FDA kept quiet about the issue of SJS in children, while Cephalon continued off-label marketing at full steam. Later, I found that the FDA had internal documents that had the same conclusion as my analysis but they had been withheld from the advisory committee.